Skip to content

NuPathe lands $30M from Quaker Bio, SR One, partners

NuPathe Inc., Conshohocken, which is developing treatments for migraine and Parkinson's, says it's raised $30 million from four local VCs and others nationally.

    by Joseph N. DiStefano
    Published 

NuPathe Inc., Conshohocken, which is developing NP101 (a skin patch for migraine headaches) and NP201 (an anti-Parkinson's Disease implant), says it's raised $30 million in Series B venture funding from six firms, led by Quaker BioVentures, a Philadelphia affiliate of Ira Lubert's Independence Capital, and SR One Ltd., the venture-capital arm of Glaxo SmithKline. Statement

» READ MORE: here

.

Other funders include Devon-based Safeguard Scientifics Inc., Bay City Capital/Birchmere Ventures, Battelle Ventures, and Pennsyvlania's state-subsidized BioAdvance Ventures, which had backed NuPathe in an earlier round.

Mark Pierce is NuPathe's chief scientific officer, Jane Hollingsworth is ceo, and Quaker Bio partner Richard S. Kollender and SR One principal Michael C. Diem had nice things to say about everyone at NuPathe in the statement announcing the $$$.